A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

• Status: Recruiting
• Trial end date: 2025-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Bupropion; Nicotine; Varenicline

Criteria

Inclusion Criteria:

• HIV positive;

• >= 18 years old

• Receiving HIV care at Yale-New Haven Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;

• Have smoked >= 100 cigarettes in lifetime;

• Currently smokes some days or every day;

• Smokes, on average, >= 5 cigarettes per day;

• Able to provide written informed consent.

Exclusion Criteria:

• Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.);

• Currently using NRT, VAR, or bupropion (defined as use in the prior 7 days);

• Self-report or urine testing confirming pregnancy, nursing, or trying to conceive;

• Life-threatening or unstable medical, surgical, or psychiatric condition;

• Inability to provide at least one collateral contact (family member or friend);

• Living out of state;

• Unable to read or understand English (except at Mount Sinai site).